Hemoperfusion and Immunomodulation.

Humans Hemoperfusion / methods Sepsis / therapy Immunomodulation Immunosuppression Therapy

Journal

Contributions to nephrology
ISSN: 1662-2782
Titre abrégé: Contrib Nephrol
Pays: Switzerland
ID NLM: 7513582

Informations de publication

Date de publication:
2023
Historique:
received: 11 01 2023
accepted: 23 02 2023
medline: 9 8 2023
pubmed: 2 6 2023
entrez: 1 6 2023
Statut: ppublish

Résumé

Recent development in sorbent technology has spurred new interest in the potential of hemoperfusion (HP) in clinical conditions such as cytokine release syndromes and sepsis. Although the role of nonselective HP in such conditions requires solid evidence and more studies, the rationale for clinical application is clearly emerging. Greater biocompatibility and safety of the new sorbents may allow easy and safe application of HP in those conditions where the innate and the adaptive immune response of the individual appears to be dysregulated. Recent results in small studies seem to confirm the plausibility for this therapeutic approach. The concept suggested by the peak concentration hypothesis justifies new studies and the application of HP in selected patients to remove the peaks of circulating mediators responsible for conditions of hyperinflammation or immunodepression.

Identifiants

DOI: 10.1159/000529885 PMID: 37263236
pubmed: 37263236
pii: 000529885
doi: 10.1159/000529885
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

142-148

Informations de copyright

© 2023 S. Karger AG, Basel.

Auteurs

Claudio Ronco (C)

Department of Medicine, University of Padova, Padova, Italy.
International Renal Research Institute of Vicenza (IRRV), Vicenza, Italy.
Department of Nephrology, San Bortolo Hospital, Vicenza, Italy.

Sara Samoni (S)

Department of Nephrology, Dialysis and Renal Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Rinaldo Bellomo (R)

Department of Critical Care, University of Melbourne, Melbourne, Victoria, Australia.
Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Victoria, Australia.
Data Analytics Research and Evaluation Centre, Austin Hospital, Melbourne, Victoria, Australia.
Department of Intensive Care, Austin Hospital, Melbourne, Victoria, Australia.
Department of Intensive Care, Royal Melbourne Hospital, Melbourne, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Hemoperfusion and Immunomodulation.
questionsmedicales.fr › Procédures de chirurgie opératoire › Circulation extracorporelle › Hémoperfusion › Hemoperfusion and Immunomodulation.
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › Sepsie › Hemoperfusion and Immunomodulation.
questionsmedicales.fr › Phénomènes du système immunitaire › Immunomodulation › Hemoperfusion and Immunomodulation.
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunosuppression thérapeutique › Hemoperfusion and Immunomodulation.